{
    "Trade/Device Name(s)": [
        "Optilite IgA Kit"
    ],
    "Submitter Information": "The Binding Site Group Ltd.",
    "510(k) Number": "K191985",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103824"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFN",
        "JIT",
        "JJX"
    ],
    "Summary Letter Date": "July 22, 2019",
    "Summary Letter Received Date": "July 25, 2019",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, And E Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgA"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Binding Site Optilite analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Immunoturbidimetry"
    ],
    "Methodologies": [
        "Quantitative immunoturbidimetry"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Optilite IgA Kit, a quantitative immunoturbidimetric assay for IgA measurement using the Optilite analyser.",
    "Indications for Use Summary": "Intended for the quantitative in vitro measurement of IgA in serum, lithium heparin or EDTA plasma to aid diagnosis of abnormal protein metabolism and immune deficiency, used alongside other clinical findings.",
    "fda_folder": "Immunology"
}